Bambusa Therapeutics (NASDAQ:BBTX) Stock Bumped Up to Hold by Wall Street Zen

Wall Street Zen upgraded shares of Bambusa Therapeutics (NASDAQ:BBTX – Free Report) to a hold rating in a report published on Saturday,Wall Street Zen reports.

Bambusa Therapeutics Stock Performance

Shares of NASDAQ:BBTX opened at $16.00 on Friday. Bambusa Therapeutics has a 52-week low of $13.60 and a 52-week high of $17.65.

Insider Transactions at Bambusa Therapeutics

In other news, Director Ra Capital Management, L.P. bought 2,500,000 shares of the business’s stock in a transaction that occurred on Monday, November 2nd. The shares were bought at an average cost of $16.00 per share, for a total transaction of $40,000,000.00. Following the acquisition, the director directly owned 5,933,787 shares in the company, valued at approximately $94,940,592. This trade represents a 72.81% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Helmut Wolfgang Jeggle purchased 375,000 shares of Bambusa Therapeutics stock in a transaction that occurred on Monday, November 2nd. The stock was acquired at an average cost of $16.00 per share, with a total value of $6,000,000.00. Following the transaction, the director owned 9,264,301 shares in the company, valued at $148,228,816. This trade represents a 4.22% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have bought 3,703,820 shares of company stock valued at $58,639,387 over the last ninety days.

About Bambusa Therapeutics

(Get Free Report)

Bambusa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing next-generation, long-acting precision bispecific antibodies designed to redefine standards of care in immunology and inflammation and fundamentally improve patient quality of life. Its pipeline includes BBT001, BBT002, BBT003 and BBT004. Bambusa Therapeutics, Inc. is based in BOSTON.

Read More

Receive News & Ratings for Bambusa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bambusa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.